Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult Nigerians
Background Reports on the evaluation of immune responses to different COVID-19 vaccines are limited. Similarly, effects of age and gender have not been well explored as variables that could impact on the vaccine-induced antibody response. Therefore, seroprevalence of anti-SARS-CoV-2 specific antibod...
Saved in:
| Format: | Article |
|---|---|
| Published: |
2023-01
|
| Tags: |
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000njm a2000000a 4500 | ||
|---|---|---|---|
| 001 | oai:repository.ui.edu.ng:123456789/12903 | ||
| 042 | |a dc | ||
| 720 | |a Onifade, A. A. |e author | ||
| 720 | |a Fowotade, A. |e author | ||
| 720 | |a Rahamon, S. K. |e author | ||
| 720 | |a Edem, V. F. |e author | ||
| 720 | |a Yaqub, S. A. |e author | ||
| 720 | |a Akande, O. K. |e author | ||
| 720 | |a Arinola, O. G. |e author | ||
| 260 | |c 2023-01 | ||
| 520 | |a Background Reports on the evaluation of immune responses to different COVID-19 vaccines are limited. Similarly, effects of age and gender have not been well explored as variables that could impact on the vaccine-induced antibody response. Therefore, seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult Nigerians was determined in this study. Methodology A total of 141 adults were enrolled into this study. Presence or absence of SARS-CoV-2 infection was confirmed by real-time reverse-transcriptase polymerase-chain reaction (RT-PCR) assay on nasopharyngeal and oropharyngeal swab specimens. Anti-SARS-CoV-2 Specific IgG and IgM antibodies were qualitatively detected using a Rapid Diagnostic Test kit. Results Pre-vaccination, 77% of the study participants had never had PCR-confirmed COVID-19 test yet 66.7% of them were seropositive for SARS-CoV-2 antibodies. Of 111 COVID-19 vaccinated participants, 69.2% and 73.8% of them had SARS-CoV-2 specific IgG post-first and second doses of COVID-19 vaccine respectively. However, 23.1% and 21.4% of the participants who have had first and second doses respectively ha no detectable anti- SARS-CoV-2 antibodies. The proportion of participants with SARS-CoV-2 specific IgG was insignificantly higher in those between the ages of 18–40 years and 41–59 years compared with individuals aged �60 years. No significant association was observed between gender and seropositivity for SARS-CoV-2 antibodies. Conclusion There is high SARS-CoV-2 antibody seroprevalence among Nigerian adults who never had PCR-confirmed COVID-19. Also, there is the need for anti-SARS-CoV-2 antibodies screening post vaccination as this could be essential in achieving herd immunity. Age and gender do not seem to have significant association with seropositivity. | ||
| 024 | 8 | |a 1932-6203 | |
| 024 | 8 | |a ui_art_onifade_seroprevalence_2023 | |
| 024 | 8 | |a Plos One 18(1), pp. 1-11 | |
| 024 | 8 | |a https://repository.ui.edu.ng/handle/123456789/12903 | |
| 245 | 0 | 0 | |a Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult Nigerians |